Based in Hospital Quirónsalud of Valencia, Spain, Initia Research, dedicated to medical research, and Initia Oncología, dedicated to Medical Oncology, were created with the aim of achieving a personalised cancer diagnosis and treatment through research and personalised, integrative, and multidisciplinary care led by its team of prestigious and experienced professionals.
Its team is headed by Dr. Andrés Poveda, Dr. Carlos Fernández Martos, and Dr. Antonio Llombart, who jointly coordinate a group of reputable medical oncologists specialising in different types of cancer: breast, gastrointestinal, lung, urological, gynaecological, melanoma, and others. Our team boasts a longstanding experience in the treatment of solid tumours. The professionals that form it are all experts in their respective fields and have published their scientific research in the most prestigious international journals.
In addition, the centre features a Precision Oncology unit where we offer our patients the latest medical advances and knowledge in genome sequencing and cancer biology.
Initia enjoys the experience, human resources, and facilities to conduct clinical trials from their initial phase through phase III, following high-quality standard operating procedures.
Code: D3615C00001
Responsable: DR. POVEDA
A Phase III Double-blind, Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant versus that of Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291)
Additional information >>Code: 1280-002
Responsable: DR. POVEDA
A Multicentre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare the Efficacy of Xentuzumab in Combination with Everolimus and Exemestane versus that of Everolimus and Exemestane in Women with HR+/HER2- Metastatic Breast Cancer and Non-visceral Disease (XENERA-1)
Additional information >>Code: I3Y-MC-JPCF
Responsable: DR. LLOMBART
A Randomised, Open-Label, Phase III Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer (MonarchE)
Additional information >>Code: 2016-004019-11
Responsable: DR. POVEDA
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in Patients with HER2+ Early Breast Cancer (TROIKA)
Additional information >>Code: MS100036-0020
Responsable: DR. FERNÁNDEZ-MARTOS
A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor Peposertib (M3814) in Combination With Capecitabine and Radiotherapy in Participants With Locally Advanced Rectal Cancer
Additional information >>Code: CL3-95005-006
Responsable: DR. GUERRERO
An Open-label, Randomised, Phase III Study Comparing Trifluridine/Tipiracil (S 95005) in Combination with Bevacizumab to Capecitabine in Combination with Bevacizumab in First-line Treatment of Patients with Metastatic Colorectal Cancer who Are Not Candidates for Intensive Therapy (SOLSTICE)
Additional information >>Code: PP06489
Responsable: DR. YAYA
A Randomised, Double-blind, Placebo-controlled Phase III Clinical Study Comparing the Efficacy and Safety of Tislelizumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Patients with Stomach Cancer
Additional information >>Code: PP06490
Responsable: DR. YAYA
A Phase 3, Double-blind, Multicentre, Placebo-controlled Study of PledOx Used Together with Standard Treatment to Prevent Chemotherapy-Induced Peripheral Neuropathy (CIPN) in the Adjuvant Treatment of Patients With Stage III or High-risk Stage II Colorectal Cancer (POLAR-A)
Additional information >>Code: BGB-A317-305
Responsable: DR. YAYA
A Phase III, Double-blind, Multicentre, Placebo-controlled Study of a New Medication, PledOx, Used Together with Standard Treatment to Prevent Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Large Bowel Cancer (POLAR-M)
Additional information >>Code: IMGN853-0417
Responsable: DR. POVEDA
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Additional information >>Right now there are no clinical trials that are no longer accepting patients for this type of cancer.
Code: ACT16146
Responsable: DR. LAVERNIA
Randomized, open-label, Phase 2 study of SAR408701 combined with pembrolizumab and pembrolizumab alone in patients with CEACAM5 and PD-L1 positive advanced/metastatic non-squamous non-small-cell lung cancer (NSQ NSCLC)
Additional information >>Right now there are no clinical trials that are no longer accepting patients for this type of cancer.
Code: ALKS 4230 001
Responsable: DR. GUERRERO
A Phase I/II Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumours (ARTISTRY)
Additional information >>Right now there are no clinical trials that are no longer accepting patients for this type of cancer.
If you speak Spanish, you may access the Spanish Clinical Trials Registry to find all of the required information in Spanish.
Find the study that you are interested in using the corresponding code. (e.g.: BGB-A31-305).
+34 96 339 04 00
Where we are
Contact us
